HLB Therapeutics Aims to Stage Comeback with RGN-259 Ahead of US Phase 3 Trial
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.4× normal (5 trading days)
Preview of a planned US Phase 3 trial; no new data or timing given.
115450 · KOSDAQ · ₩115450 · HLB테라퓨틱스
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.4× normal (5 trading days)
Preview of a planned US Phase 3 trial; no new data or timing given.
Also known as: HLB Therapeutics / HLB테라퓨틱스 / 115450 / KRX:115450
Source: KRX statistical information